Environment management programmes at IP Uni for 2025-26 academic year
Tired of too many ads? go ad free now
These programmes provide a platform for students to explore sustainable solutions and pursue a career dedicated to environmental protection. The university is offering three courses in this domain: MSc in Environment Management, MSc in Applied Geoinformatics, and BSc in Environment Management.
All three are conducted at the University School of Environment Management, located on the university's Dwarka campus.
Each of the two postgraduate programmes—MSc in Environment Management and MSc in Applied Geoinformatics—has an intake capacity of 30 students, while the undergraduate BSc programme offers 60 seats.
"Admissions will be based on CUET scores, but candidates will be considered under this category only after merit lists from national-level entrance examinations or university-conducted tests for affiliated programmes are exhausted," said an official.
Applicants who already secured admission through other entrance routes will not be eligible to apply under the CUET-based process. Interested candidates can submit their applications online by July 30 through the official university website.
A university official noted that there was a significant rise in demand for these programmes globally, reflecting the growing importance of environmental management and the increasing role of emerging technologies in this field.
Tired of too many ads? go ad free now
"The curriculum in these courses is designed to equip students with both theoretical knowledge and practical skills needed to address contemporary environmental challenges," the official added.
In a step toward inclusive education, the university has also introduced a new quota for orphaned children, effective from the 2025-26 academic session. This initiative is in addition to the single girl child quota, which was launched last year. Under the new policy, one supernumerary seat will be reserved in each school and programme for eligible orphaned candidates.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
2 hours ago
- Mint
Indian contract drug makers timed their IPOs right. But is the business worth the premium?
An anticipated shift in the global pharmaceutical supply chain away from China has investors excited about Indian contract research, development and manufacturing organisations (CRDMOs), companies that offer services from early-stage drug discovery to late-stage drug development. Export-focused CRDMOs including Anthem Biosciences, Sai Life Sciences and Divi's Laboratories are trading at expensive valuations, reflecting investor enthusiasm as innovator drug companies look at diversifying and derisking their operations. However, experts cautioned that while CRDMOs are expected to post high growth, their financial performances have yet to reflect it. Bengaluru-based Anthem Biosciences made a stellar debut on the stock exchanges on 21 July, listing on the National Stock Exchange at a premium of 27 percent over its initial public offering price of ₹ 570. The IPO, with an issue size of ₹ 3,395.79 crore, was subscribed 67.42 times. Anthem's stock traded at a price-to-earnings (PE) ratio of 93.24 on 25 July. 'The good news is that… China is a behemoth. So, we have that much headroom to grow,' Ajay Bhardwaj, managing director and chief executive officer, told Mint earlier. About 65% of India's imported bulk drugs and advanced drug intermediates worth $3.5 billion in FY25 came from China, according to the commerce ministry. The government wants to strengthen local manufacturing through an upgraded drugs production-linked incentive scheme as it pushes for self-sufficiency in bulk drugs that go into manufacturing medicines. The Indian CRDMO industry today is worth $3-3.5 billion, making up only 2-3% of the global CRDMO market, which is worth $145 billion. It grew at a compound annual growth rate of 15% from 2019-2024, according to a recent report by BCG and IPSO. The industry is at a tipping point, with strong fundamentals and massive headroom to grow, fueled by competitive advantage in small molecule capabilities, faster startup time, focus on quality and cost advantages, the report noted. Unlike CRDMOs, CDMOs (contract development and manufacturing organisations) are typically involved in manufacturing already commercialised drugs. Sai Life Sciences, which made its market debut in December 2024, traded at ₹ 837 on 25 July, close to its high of about ₹ 851, valuing the company at roughly 102 times trailing earnings and about 8.2 times book value. Divi's Laboratories and Syngene International also traded at premiums, at a PE ratio of 80.31 and 55.09, respectively. In comparison, generic pharmaceutical giants are valued relatively modestly: Sun Pharmaceutical Industries trades at a PE ratio of 37.37, Dr Reddy's Laboratories at 18.84, and Cipla at 23.53. Sai Life Sciences shares are up over 18% since listing on the NSE. Divi's Laboratories gained 35.56% from 30 July 2024 to 28 July 2025, Piramal Pharma rose 20.36%, while Syngene International's shares were down 12.72%. Syngene International, a unit of biopharmaceutical company Biocon, kicked off this fiscal's earnings season last week. It posted an 11% year-on-year rise in revenue from operations to ₹ 875 crore for Q1, a robust start compared to its FY25 performance (4% revenue growth YoY). The management maintained its expectation of revenue growth in the mid‑teens for FY26. Sai Life Sciences delivered 16% revenue growth to ₹ 1,695 crore in FY25. Divi's reported a 19% year-on-year rise in full-year revenue to ₹ 9,360 crore in FY25, while net profit surged 37% to ₹ 2,191 crore. Divi's is expected to post revenue growth of 18% year-on-year in Q1FY26, according to brokerage BNP Paribas. 'The Indian CDMO sub-sector presents a highly promising opportunity as investors view it as a direct beneficiary of the China+1 thematic,' Sunil Khaitan, managing director leading financing in India at Goldman Sachs, told Mint. 'We expect the capital markets activity in this space to further accelerate over the next 6-12 months.' The China-plus one theme – to diversify supply chains and reduce overdependence on China – is a key driver, but it's not just that. CRDMOs are on an aggressive capacity expansion track as they anticipate winning over more clients in the future and bank on technological niches to cater to biotech companies as demand for new technologies and drugs grows. Anthem has expertise in new chemical entities as well as biologics (drugs made from living organisms or their components) and capabilities to work on RNAi (a gene regulatory mechanism), antibody drug conjugates that target and kill cancer cells, peptides (short chains of amino acids), lipids, and oligonucleotides (synthesised nucleic acids). OneSource Specialty Pharma, a subsidiary of Strides Pharma, which listed in January, expects its focus on niche areas such as biologics, drug substances, injectables, and drug-device combinations to drive growth. Its offerings in drug-device combinations, particularly for GLP-1s (hormones that regulate blood sugar levels), which are often sold in pen-filled devices, is expected to be a major growth opportunity. 'We are currently executing a 5x expansion of our cartridge-filling capabilities to meet our customer demand and which will significantly boost future revenue,' CEO Neeraj Sharma told Mint in an emailed response. Anthem Biosciences and Sai Life Sciences did not respond to Mint's queries. Investors are looking at CRDMOs not just for potential growth driven by these tailwinds but also as diversification of their portfolios, experts said. Opportunities in traditional pharma companies with a focus on domestic formulations and US generics are drying up because of a slowdown in new approvals and regulatory issues. 'The investor would like to have exposure to companies and segments which have the potential for high growth and themes of shifting manufacturing from China to India,' Tausif Shaikh, healthcare and pharma analyst at BNP Paribas, told Mint. While CRDMOs have reported steady, mid-teen revenue growth, their performance has not been encouraging enough even as valuations remain expensive, Shaikh pointed out. Unlike sectors such as healthcare services, where one can gauge a company's performance based on metrics like hospital bed occupancy and average revenue per bed, for contract drug manufacturers, management commentary is the main indicator of the company's expected growth and performance, said Shaikh. Most companies report an uptick in interest from innovators to hire their services and have embarked on aggressive capacity expansion. Syngene plans to boost its biologics manufacturing footprint in FY26 through its newly acquired US facility for $36.5 million. Divi's Laboratories is undertaking a ₹ 650-700 crore capacity expansion at its existing facilities, while Sai Life Sciences has completed the second phase of its Bidar Unit IV capacity expansion for small-molecule active pharmaceutical ingredients and intermediates. On the back of this, the growth outlook remains strong. "Earnings are expected to be strong for export-oriented CDMOs for the next 2-3 years considering the capex projects and potential addition of new molecules,' Shrikant Akolkar, pharma equity research analyst at brokerage Nuvama, told Mint. However, the CDMO business is non-linear, Akolkar said, adding that one must pay attention to the annual performance and not a couple of quarters of number misses.
News18
5 hours ago
- News18
Is Earth In Danger? Mystery Object May Be ‘Hostile' Alien Spacecraft Approaching Our Planet
The mystery object is on a stealth path through the inner Solar System, and Earth's fastest rockets aren't nearly quick enough to intercept it A strange object the size of a small city is hurtling through our Solar System, and a team of scientists think it might not be just a comet. In fact, they're toying with a far more dramatic possibility: that it could be alien technology, potentially even 'hostile", hiding behind the Sun. The object, officially named 3I/ATLAS (and earlier known as A11pl3Z), was first spotted on July 1 by a telescope in Chile. Within 24 hours, scientists confirmed it had come from outside our Solar System, making it just the third known interstellar visitor ever recorded, according to Live Science. It's not small either. Estimates say it measures 10 to 20 kilometres wide, making it potentially larger in area than Manhattan, and it's tearing through space at over 130,000 mph (60 km per second). Over the next few months, it's expected to swing past Jupiter, Mars and Venus, before disappearing behind the Sun in late November, out of sight from Earth. Is It Just A Rock Or Something More? A new, non-peer-reviewed scientific paper published on July 16 has turned heads for suggesting that this might not be a comet at all, but an extraterrestrial spacecraft on a stealth mission. The study was written by Harvard astrophysicist Avi Loeb, known for his bold claims about alien life, along with researchers Adam Hibberd and Adam Crowl from the Initiative for Interstellar Studies in London. They're not claiming this is definitely alien, but they are proposing a testable theory. In their words, it's 'an interesting exercise in its own right," worth exploring 'irrespective of its likely validity." Still, they warn that if the theory does hold true, the consequences could be serious, even requiring 'defensive measures," though they admit those might not be effective. A Suspicious Flight Path? So why the suspicion? Loeb and his co-authors point to the object's trajectory, which is oddly precise. It's moving faster than the last interstellar visitor, ʻOumuamua', and it entered the Solar System from a different angle, which, they suggest, could offer 'various benefits to an extraterrestrial intelligence." Even more puzzling, the object's orbital path is aligned with Earth's within just 5 degrees. Loeb told Newsweek that the odds of this happening randomly are only 0.2 per cent. In his view, this could mean the object is deliberately targeting the inner Solar System, something one might expect from alien tech. Then there's the route itself. 3I/ATLAS is set to make close passes by three major planets — Venus, Mars and Jupiter — which scientists say is highly improbable without calculated guidance. According to the Mirror UK, the chances of such a path occurring by chance are less than 0.005 per cent. The timing also raises eyebrows. In late November, the object will pass behind the Sun, making it invisible to Earth-based telescopes. Loeb speculates this might not be a coincidence. 'This could be intentional to avoid detailed observations from Earth-based telescopes when the object is brightest or when gadgets are sent to Earth from that hidden vantage point," he wrote in a blog post. They even suggest the planetary flybys could allow for 'gadgets" to be planted, spy tech dropped off on Mars, Venus or Jupiter en route. Unfortunately, even if Earth wanted to investigate, we simply can't catch up. Loeb notes that our fastest rockets can only reach a third of 3I/ATLAS's speed, making a rendezvous impossible with current technology. The theory has sparked curiosity online, but not everyone is convinced. Samantha Lawler, an astronomer at Canada's University of Regina, says the evidence points clearly to a natural comet, one that was simply ejected from another solar system, as billions of others likely have been. Others were more critical. Chris Lintott from the University of Oxford, who helped trace the object's galactic origin, dismissed the alien theory outright, calling it 'nonsense on stilts" and saying it undermines the real science being done by teams worldwide. Even Loeb concedes the most probable explanation is that 3I/ATLAS is just another icy interstellar wanderer. 'By far, the most likely outcome will be that 3I/ATLAS is a completely natural interstellar object, probably a comet," he said. This Isn't Loeb's First Rodeo This isn't the first time Loeb has floated the idea of alien probes in our cosmic neighbourhood. Back in 2022, he revived global buzz around ʻOumuamua', the cigar-shaped interstellar object spotted in 2017. He suggested it could be a 'lightsail" — a spacecraft powered by light particles — or even a deliberately sent probe from an alien civilisation. 'Oumuamua may be a fully operational probe sent intentionally to Earth vicinity by an alien civilisation," he wrote at the time. So What Now? For now, astronomers across the world are closely tracking 3I/ATLAS as it continues its journey toward the Sun. Whether it turns out to be a piece of cosmic spyware or just an unusually fast space rock, it has already reignited one of humanity's oldest questions — are we really alone out here? About the Author News Desk The News Desk is a team of passionate editors and writers who break and analyse the most important events unfolding in India and abroad. From live updates to exclusive reports to in-depth explainers, the Desk More Get breaking news, in-depth analysis, and expert perspectives on everything from geopolitics to diplomacy and global trends. Stay informed with the latest world news only on News18. Download the News18 App to stay updated! tags : alien invasion comet spacecraft view comments Location : New Delhi, India, India First Published: July 28, 2025, 14:01 IST News world Is Earth In Danger? Mystery Object May Be 'Hostile' Alien Spacecraft Approaching Our Planet Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Indian Express
7 hours ago
- Indian Express
Study led by IISER Pune decodes mechanisms that help plants regrow injured parts with original shape
Gardeners are often seen pruning shrubs or tree branches to maintain plant health and promote fresh growth. Soon, however, the pruned branches regrow with stunning resemblance to their original form. An international group of scientists, led by biologists at the Indian Institute of Science Education and Research, Pune (IISER), has now zeroed in on the key mechanisms in plants that help restore damaged parts to their original shape. Unlike animal cells, plant cells are far more rigid and depend more on growth rates and anisotropy (how a material's physical characteristics change depending on its direction) during cell regeneration. Roots are important facilitators that support nutrient intake. Their naturally tapered shape and conical tip aid better soil penetration. When they get damaged due to natural or external causes, it is observed that the lost cell types and layers get restored and the root regrows to the original tapered shape. In the latest paper published on July 25 in the journal Current Biology, mathematicians and physicists from IISER, Pune and Thiruvananthapuram, Netherlands' Wageningen University, and UK-based John Innes Centre, have attempted to track the mechanisms that may be responsible for restoring the root's tapered shape. In the study, the researchers describe a distinct geometric pattern as per which plant roots regrow after being damaged. This understanding, they said, could help establish fundamental cellular processes, like cell shape and cell regeneration in plants and, in particular, plants vital for food cultivation and securing food security. Instinctive responses of injured roots The group studied the regeneration of the Arabidopsis thaliana root after it was surgically chipped off. They observed notable behaviour in the root regrowth from the 12th hour since being chipped. Instinctively, the injured root's first response was to generate new cells at the wound site. And their goal was to remain oriented in the right direction and help restore the shape and function of the root and maintain its original function. 'The usual cuboidal root cells got morphed into rhomboid shapes. These altered cells then divided diagonally, producing triangular prism-like cells. The diagonal divisions redirected the growth of neighbouring cells along a slanted path — collectively recreating the lost tapered tip,' Kalika Prasad, biologist at IISER-Pune and co-author of the paper, told The Indian Express. After about 18-19 hours post-cutting, the previously flat root end had grown and bulged. By 24 hours, it had become more prominent, indicating the onset of some trigger mechanisms. Corresponding to about 12 hours post the injury, the researchers said, a mechanical tension was noted developing during the growth stage of the injured root. And this tension, they said, guided and controlled the new cells to align and develop in a certain geometric manner. The root tip has multiple cell layers. While cells in the outermost layer grow slower, the cells present in the innermost layer grow rapidly. 'This differential growth then leads to build up in mechanical tension within the cells and, as a response, their shape or geometry starts aligning. In the end, we found the regrown root to have restored perfectly with respect to cell types and the shape. It functioned optimally like an uninjured root,' Prasad said. Similar post-injury cell regeneration behaviour was demonstrated by a mustard plant called Brassica, which the team tested.
